Synthesis and evaluation of 6-heteroarylamino-2,4,5-trimethylpyridin-3-ols as inhibitors of TNF-α-induced cell adhesion and inflammatory bowel disease

Current and emerging therapeutic targets for IBD

(2017) Markus F. Neurath   Nature Reviews Gastroenterology & Hepatology

In vitro and in vivo inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory bowel disease

(2016) Suhrid Banskota et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases

(2016) Caroline Meyer Olesen et al.   PHARMACOLOGY & THERAPEUTICS

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

(2015) L Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Integrins and adhesion molecules as targets to treat inflammatory bowel disease

(2015) Ivana Bravatà et al.   CURRENT OPINION IN PHARMACOLOGY

The global burden of IBD: from 2015 to 2025

(2015) Gilaad G. Kaplan   Nature Reviews Gastroenterology & Hepatology

Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease

(2015) Giovanni Monteleone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Design and synthesis of 5-[(2-chloro-6-fluorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole (AKP-001), a novel inhibitor of p38 MAP kinase with reduced side effects based on the antedrug concept

(2014) Koichi Hasumi et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Structure–activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12/23 inhibitor, APY0201

(2014) Nobuhiko Hayakawa et al.   BIOORGANIC & MEDICINAL CHEMISTRY

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

(2014) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

New Drugs on the Horizon for IBD

(2014) Bruce E. Sands   DIGESTIVE DISEASES

6-Amino-2,4,5-trimethylpyridin-3-ols: A new general synthetic route and antiangiogenic activity

(2014) Dong-Guk Kim et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Protective effect of 7-O-succinyl macrolactin A against intestinal inflammation is mediated through PI3-kinase/Akt/mTOR and NF-κB signaling pathways

(2014) Sumin Park et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

IL-10: The Master Regulator of Immunity to Infection

(2014) Kevin N. Couper et al.   JOURNAL OF IMMUNOLOGY

Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target

(2013) Mariangela Allocca et al.   CURRENT DRUG TARGETS

Keeping the Bowel Regular

(2013) David J. Gibson et al.   INFLAMMATORY BOWEL DISEASES

IL-10 and IL-10 receptor defects in humans

(2012) Erik-Oliver Glocker et al.   Annals of the New York Academy of Sciences

IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+Th17 cells

(2012) Margherita Coccia et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Regioselective Synthesis of 2-Amino-Substituted 1,3,4-Oxadiazole and 1,3,4-Thiadiazole Derivatives via Reagent-Based Cyclization of Thiosemicarbazide Intermediate

(2012) Seung-Ju Yang et al.   JOURNAL OF ORGANIC CHEMISTRY

Genetics and pathogenesis of inflammatory bowel disease

(2011) Bernard Khor et al.   NATURE

Clotrimazole Ameliorates Intestinal Inflammation and Abnormal Angiogenesis by Inhibiting Interleukin-8 Expression through a Nuclear Factor- B-Dependent Manner

(2008) D. Thapa et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS